Life expectancy less than 3 months before COVID-19 at the discretion of the investigator Invasive mechanical ventilation ≥72 hours at time-point of randomization History of severe asthma, atopic allergy, severe immune or chronic inflammatory conditions (e.g. systemic lupus erythematosus) Resuscitation > 45 minutes Hypersensitivity to the active substance, to Adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies Currently receiving systemic chemotherapy and/or radiotherapy Pre-existing severe chronic liver disease (i.e. Child-Pugh C) before COVID-19 hospitalization Pre-existing dialysis therapy before COVID-19 hospitalization Note: RRT and/ or ECMO (initiated during COVID-19 hospitalization) are not an exclusion criteria

Life expectancy less than 3 months before COVID-19 at the discretion of the investigator Invasive mechanical ventilation ≥72 hours at time-point of randomization History of severe asthma, atopic allergy, severe immune or chronic inflammatory conditions (e.g. systemic lupus erythematosus) Resuscitation > 45 minutes Hypersensitivity to the active substance, to Adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies Currently receiving systemic chemotherapy and/or radiotherapy Pre-existing severe chronic liver disease (i.e. Child-Pugh C) before COVID-19 hospitalization Pre-existing dialysis therapy before COVID-19 hospitalization Note: RRT and/ or ECMO (initiated during COVID-19 hospitalization) are not an exclusion criteria